HNN3.0
Register
Register
Register

Project cooperationUpdated on 16 January 2026

Multi-omics (AI) Biomarker & Predictive Model Co-Development for Precision Medicine

CEO & Co-Founder at Nexyra Advanced Research

Madrid, Spain

About

Nexyra Advanced Research builds AI-powered multi-omics and multimodal intelligence to turn molecular and clinical data into actionable insights for diagnostics, patient stratification, and biomedical R&D decision-making.

Systems biology applied to multi-omics captures complex mechanisms beyond single-marker approaches and addresses biological heterogeneity that often limits clinical translation and R&D success. We integrate multi-layer omics (e.g., genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome) with clinical variables to develop robust signatures and predictive models tailored to specific cohorts/populations.

What we propose (Project cooperation)
A collaboration with hospitals, clinical groups, biotechs, or pharma to:

  • Discover and validate biomarkers (diagnostic / stratification / monitoring).

  • Build predictive and prognostic models integrating multi-omics + clinical data (AI).

  • Prioritize therapeutic targets and support translational R&D decisions.

Preferred use cases (examples)

  • Oncology (e.g., tumor microenvironment and immunometabolism; meta-analysis of public cohorts).

  • Complex diseases with high biological heterogeneity (stratification and treatment response).

  • Longevity and precision health (biological age, pathway regulation, personalized interventions).

Typical deliverables

  • Reproducible pipeline (QC, harmonization, multi-omics integration, statistical analysis, ML).

  • Prioritized biomarker/target list with evidence, functional interpretation, and actionable recommendations.

  • Scientific report and, optionally, stakeholder-ready visualizations/dashboards.

What we need from the partner

  • Access to cohorts and/or samples (retrospective or prospective) plus minimum clinical metadata.

  • A “clinical champion” to define endpoints and support biological/clinical validation.

  • Interest in co-publication, co-development, licensing, or progression into validation/clinical study phases.

Collaboration model

  • NDA + collaboration agreement (roles, governance, milestones, IP/background IP).

  • Options: (i) fee-for-service + milestone bonuses, (ii) co-development with shared IP, (iii) consortium / competitive grants.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

Type

  • Consortium/Coordinator seeks Partners
  • Partner seeks Consortium/Coordinator

Attached files

Organisation

Nexyra Advanced Research

Start-up

Madrid, Spain

Similar opportunities

  • Project cooperation

    Advancing Horizon Europe projects through microbiota and metabolomics for translational and clinical research

    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Silvia Angeletti

    Full Professor Clinical Pathology and Head of Laboratory Unit at Fondazione Policlinico Universitario Campus Bio-Medico

    Rome, Italy

  • Project cooperation

    Multimodal AI for Cardiac Risks Prediction and Diagnosis

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Alessandro Perelli

    Lecturer in Artificial Intelligence at University of Glasgow

    Glasgow, United Kingdom

  • Project cooperation

    Seeking candidates for MSCA Postdoctoral Fellowships in Multimodal Foundation AI Models for Cardiac and Healthcare Applications

    • Consortium/Coordinator seeks Partners
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Alessandro Perelli

    Lecturer in Artificial Intelligence at University of Glasgow

    Glasgow, United Kingdom